Reversal of epigenetic aging and immunosenescent trends in humans
Fahy GM, Brooke RT, Watson JP
Published in Aging Cell
Methodology
One-year uncontrolled interventional trial (TRIIM) of growth hormone, DHEA and metformin intended to regenerate the thymus, with four epigenetic age estimators
Key Findings
Mean epigenetic age was approximately 1.5 years less than baseline after 1 year of treatment, with GrimAge showing a 2-year decrease persisting six months after stopping treatment
Conclusions
Epigenetic age measures can move downward under intervention, but this pilot used pharmaceuticals, not supplements, and had no control arm
Limitations
Nine participants, no placebo control, drug-based protocol
Outcomes Measured
we observed protective immunological changes, improved risk indices for many age-related diseases, and a mean epigenetic age approximately 1.5 years less than baseline after 1 year of treatment
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.